Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer

Jue Liu; Ming Zhu; Xue Xia; Yuliang Huang; Qunfeng Zhang; Xiaoxu Wang

doi:10.18632/oncotarget.13208

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer

Jue Liu _, Ming Zhu, Xue Xia, Yuliang Huang, Qunfeng Zhang and Xiaoxu Wang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:85151-85162. https://doi.org/10.18632/oncotarget.13208

Metrics: PDF 2118 views | HTML 2076 views | ?

Abstract

Jue Liu1,*, Ming Zhu3,*, Xue Xia2,*, Yuliang Huang1, Qunfeng Zhang1, Xiaoxu Wang2

1Department of Obstetrics and Gynecology, The Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, P.R. China

2Department of Orthopaedics, The Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, P.R. China

3Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Xiaoxu Wang, email: [email protected]

Keywords: cervical cancer, JMJD1A, c-Myc, prognosis, immunohistochemistry

Received: June 03, 2016 Accepted: October 26, 2016 Published: November 08, 2016

ABSTRACT

Jumonji domain-containing protein 1A (JMJD1A) plays a key role in the development and progression of several cancers. Here, we showed that the expression of JMJD1A is increased in cervical cancer cells and tissues, and that suppression of JMJD1A inhibits proliferation, migration, and invasion of cervical cancer cells. JMJD1A induced transcription of c-Myc, which is essential for cervical cancer growth and progression. Clinical data showed that JMJD1A expression correlated with lymph node metastasis (P=0.031) and FIGO stage (P=0.007). Increased c-Myc levels were associated with tumor differentiation (P=0.007) and FIGO stage (P<0.001). JMJD1A protein levels correlated with c-Myc expression (P<0.001), and high co-expression of the two proteins correlated with a poor prognosis. Survival analysis showed that JMJD1A and c-Myc levels are independent prognostic factors for cervical cancer patients. These results suggest that JMJD1A is a promising therapeutic target in cervical cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13208

Publication Alerts

Research Papers:

Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer

Abstract